RESPONSE TO LETTER

“Common Ophthalmic Preservatives in Soft Contact Lens Care Products: Benefits, Complications, and a Comparison to Non-Preserved Solutions” [Response to Letter]

Dear editor

We thank Drs. Erdinest, London, and Levinger for their interest in our article discussing common ophthalmic preservatives in soft contact lens care products.\(^1\) We agree with the authors regarding the physiological effects of polyquaternium-1, polyhexamethylene biguanide (PHMB), and/or borate on the ocular surface. While we did comment on the cytotoxicity of polyquaternium-1 affecting epithelial tight junctions,\(^2\) we did not specify this as oxidative stress or acknowledge the role of tumor necrosis factor alpha (TNF-\(\alpha\)) secretion, and we appreciate the added detail. Similarly, we acknowledged the role of PHMB alone and PHMB plus boric acid in causing significant corneal staining.\(^3\)\(^-\)\(^7\) As a literature review, the goal of our manuscript was to capture the current state of the field, and unfortunately, we were unable to include every available reference given the extensive scope of the article. Nevertheless, their comments do augment our report.

We also agree that it would be pertinent to consider the effects of MPS preservatives in relationship to corneal lenses, scleral lenses, and hybrid contact lenses. However, the purpose of our manuscript, as indicated by the title, was to highlight soft contact lens care products. Thus, while this topic was outside of the scope of our manuscript, we agree that a future review that focuses on specialty contact lens care products would benefit the community.

Disclosure

Dr. Lindsay A. Sicks reports personal fees and Honoraria (Speaker’s Alliance) from Alcon Laboratories outside the submitted work. Dr. Andrew D. Pucker has received financial research support from Alcon Research, LLC, Art Optical, Bausch & Lomb, Euclid Systems, Contamac, National Eye Institute, and Paragon Vision Sciences, and consulted for Alcon Research, LLC, CooperVision, EpiTech, EyeGate Pharmaceuticals, Inc, Kala Pharmaceuticals, Nevakar Inc, and Optikal Care Inc over the past three years. The authors report no other conflicts of interest in this communication.

Correspondence: Andrew D Pucker
Email apucker@uab.edu

Chelsea S Bradley\(^1\)
Lindsay A Sicks\(^1\)
Andrew D Pucker\(^2\)
\(^1\)Illinois College of Optometry, Chicago, IL, USA; \(^2\)School of Optometry, University of Alabama at Birmingham, Birmingham, AL, USA
References


